Find a Clinical Trial

Trial Description: This research study involves Niraparib as a possible treatment for triple negative breast cancer.

• Conditions: residual disease, triple negative breast cancer
• Phase: I
• Trial ID: NCT03945721
• Protocol ID: 19-055

Trial Description: This study is designed to determine the efficacy and safety of durvalumab in combination with novel oncology therapies with or without paclitaxel and durvalumab + paclitaxel for first-line metastatic triple negative breast cancer

• Conditions: triple negative breast neoplasms
• Phase: I/II
• Trial ID: NCT03742102
• Protocol ID: 21-198

Trial Description: This research study is studying immunotherapy as a possible treatment for metastatic Triple Negative Breast Cancer (TNBC) in participants who are HLA-A2+. The drugs involved in this study are: - PVX-410 - Pembrolizumab - Hiltonol - Montanide

• Conditions: metastatic breast cancer, triple negative breast cancer
• Phase: I
• Trial ID: NCT03362060
• Protocol ID: 17-328

Trial Description: This research study is studying to evaluate sacituzumab govitecan for individuals with localized triple negative breast cancer (TNBC) The names of the study drugs involved in this study is: - Sacituzumab govitecan (SG) - Pembrolizumab (combination therapy with SG)

• Conditions: er-negative breast cancer, her2-negative breast cancer, invasive breast cancer, pr-negative breast cancer, triple negative breast cancer
• Phase: II
• Trial ID: NCT04230109
• Protocol ID: 19-578

Trial Description: This is a two-part open label, non-randomized, Phase 2, study of ZEN003694 in combination with Talazoparib in patients with TNBC without germline mutations of BRCA1 or BRCA2. Part 1 is a dose escalation and Part 2 is a Simon 2-Stage design. There are 3 expansion cohorts: Expansion Cohort A (combination treatment in post-TROP2-ADC patients), Expansion Cohort B (ZEN003694 monotherapy), and Expansion Cohort C (combination treatment in TROP2-ADC-naive patients

• Conditions: triple negative breast cancer
• Phase: II
• Trial ID: NCT03901469
• Protocol ID: 22-515

Trial Description: This research is studying the effect of Antibody-Drug Conjugate Sacituzumab Govitecan in Combination with the Poly (Adenosine Diphosphate [ADP]-Ribose) Polymerase (PARP) Inhibitor Talazoparib in Patients with Metastatic Triple-Negative Breast Cancer.

• Conditions: breast cancer
• Phase: I/II
• Trial ID: NCT04039230
• Protocol ID: 19-239

Trial Description: This research is being done to evaluate the safety and effectiveness of Onvansertib in combination with Paclitaxel in triple-negative breast cancer (TNBC) that has spread to other parts of the body. The names of the study interventions involved in this study are: - Onvansertib - Paclitaxel

• Conditions: breast cancer, her2-negative breast cancer, hormone receptor negative breast carcinoma, hormone receptor/growth factor receptor-negative breast cancer, inflammatory breast cancer, invasive breast cancer, locally advanced breast cancer, metastatic breast cancer, triple negative breast cancer (tnbc), unresectable breast carcinoma
• Phase: I/II
• Trial ID: NCT05383196
• Protocol ID: 22-008

Trial Description: This research study is studying a drug called Carboplatin with or without another study drug, Nivolumab as a possible treatment for triple-negative breast cancer that has spread to other parts of the body. The interventions involved in this study are: - Carboplatin - Nivolumab

• Conditions: breast cancer
• Phase: II
• Trial ID: NCT03414684
• Protocol ID: 17-512

Trial Description: This research study is studying the combination of a drug called atezolizumab and a radiation procedure called stereotactic radiosurgery (SRS) as a possible treatment for triple-negative breast cancer that has spread to the brain. The interventions involved in this study are: - Atezolizumab - Stereotactic radiosurgery (SRS)

• Conditions: breast cancer
• Phase: II
• Trial ID: NCT03483012
• Protocol ID: 17-519

Trial Description: This research study involves testing the safety and efficacy of an investigational intervention for patients with triple-negative breast cancer (TNBC) that has spread, or metastasized, to other parts the body and is PD-L1-negative. The names of the study interventions involved in this study are: - Sacituzumab govitecan (Trodelvy™;IMMU-132) - Pembrolizumab (Keytruda®; MK-3475)

• Conditions: breast cancer, pd-l1 negative, triple negative breast cancer
• Phase: II
• Trial ID: NCT04468061
• Protocol ID: 20-166

Trial Description: This phase Ib trial tests the safety and tolerability of ZEN003694 in combination with an immunotherapy drug called pembrolizumab and the usual chemotherapy approach with nab-paclitaxel for the treatment of patients with triple negative-negative breast cancer that has spread to other parts of the body (advanced). Paclitaxel is in a class of medications called antimicrotubule agents. It stops cancer cells from growing and dividing and may kill them. Nab-paclitaxel is an albumin-stabilized nanoparticle formulation of paclitaxel which may have fewer side effects and work

• Conditions: anatomic stage iii breast cancer ajcc v8, anatomic stage iv breast cancer ajcc v8, locally advanced triple-negative breast carcinoma, metastatic triple-negative breast carcinoma, unresectable triple-negative breast carcinoma
• Phase: I
• Trial ID: NCT05422794
• Protocol ID: 22-589

Trial Description: The purpose of this study is to determine if a combination of two drugs ipatasertib and atezolizumab works as a treatment for residual cancer in the breast or lymph nodes and have circulating tumor DNA in the blood. This research study involves the following investigational drugs: - Sacituzumab govitecan - Atezolizumab

• Conditions: breast cancer, circulating tumor dna, residual cancer, triple negative breast cancer
• Phase: II
• Trial ID: NCT04434040
• Protocol ID: 20-028

. Binimetinib is in a class of medications called kinase inhibitors. It works by blocking the action proteins called MEK1 and MEK2, that signal cancer cells to multiply. It may help keep cancer cells from growing and spreading. There is pre-clinical evidence that using ZEN003694 and binimetinib together may shrink or stabilize cancers studied in this trial. There are two parts of this study; dose escalation and dose expansion. In the dose escalation part of this study, different people will get different doses of the study drugs ZEN003694 and binimetinib. In the dose expansion part of this study, the highest dose with manageable side effects will be given to additional people. This will help to understand the side effects that may happen with this drug combination.

• Conditions: advanced malignant solid neoplasm, metastatic malignant solid neoplasm, refractory malignant solid neoplasm, triple-negative breast carcinoma, unresectable malignant solid neoplasm
• Phase: I
• Trial ID: NCT05111561
• Protocol ID: 22-243

Trial Description: This randomized phase II trial studies how well multi-epitope folate receptor alpha peptide vaccine, sargramostim (GM-CSF), and cyclophosphamide work to prevent the recurrence of stage 1-3 triple negative breast cancer. Vaccines made from a person's white blood cells mixed with tumor proteins may help the body build an effective immune response to kill tumor cells. Drugs used in chemotherapy, such as cyclophosphamide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving multi-epitope folate receptor alpha peptide vaccine, sargramostim (GM-CSF), and cyclophosphamide may work well together to prevent cancer recurrence after surgery and other standard treatments for triple negative breast cancer.

• Conditions: bilateral breast carcinoma, breast inflammatory carcinoma, stage ib breast cancer ajcc v7, stage ii breast cancer ajcc v6 and v7, stage iia breast cancer ajcc v6 and v7, stage iib breast cancer ajcc v6 and v7, stage iii breast cancer ajcc v7, stage iiia breast cancer ajcc v7, stage iiib breast cancer ajcc v7, stage iiic breast cancer ajcc v7, triple-negative breast carcinoma, unilateral breast carcinoma
• Phase: II
• Trial ID: NCT03012100
• Protocol ID: 18-078

Trial Description: The primary objective of this study is to compare the progression-free survival (PFS) between sacituzumab govitecan-hziy (SG) and pembrolizumab versus treatment of physician's choice (TPC) and pembrolizumab in participants with previously untreated, locally advanced inoperable or metastatic triple-negative breast cancer, whose tumors express programmed cell death ligand 1 (PD-L1).

• Conditions: pd-l1 positive, triple negative breast cancer
• Phase: III
• Trial ID: NCT05382286
• Protocol ID: 22-485

Trial Description: Avelumab in combination with talazoparib will be investigated in patients with locally advanced (primary or recurrent) or metastatic solid tumors, including non-small cell lung cancer (NSCLC), triple negative breast cancer (TNBC), hormone receptor positive (HR+) breast cancer, recurrent platinum sensitive ovarian cancer, urothelial cancer (UC), and castration resistant prostate cancer (CRPC).

• Conditions: avelumab in combination with talazoparib will be investigated in patients with locally advanced (primary or recurrent) or metastatic solid tumors
• Phase: I/II
• Trial ID: NCT03330405
• Protocol ID: 17-687

Trial Description: The primary objective of this study is to compare the efficacy of sacituzumab govitecan to the treatment of physician's choice (TPC) as measured by independently-reviewed Independent Review Committee (IRC) progression-free survival (PFS) in participants with locally advanced or metastatic triple-negative breast cancer (TNBC) previously treated with at least two systemic chemotherapy regimens for unresectable, locally advanced or metastatic disease, and without brain metastasis at baseline.

• Conditions: breast cancer
• Phase: III
• Trial ID: NCT02574455
• Protocol ID: 17-495

Trial Description: This randomized phase III trial studies how well cisplatin or carboplatin (platinum based chemotherapy) works compared to capecitabine in treating patients with remaining (residual) basal-like triple-negative breast cancer following chemotherapy after surgery (neoadjuvant). Drugs used in chemotherapy, such as cisplatin, carboplatin and capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether cisplatin or carboplatin is more effective than capecitabine in treating patients with residual triple negative basal-like breast cancer.

• Conditions: estrogen receptor negative, her2/neu negative, invasive breast carcinoma, progesterone receptor negative, stage ii breast cancer, stage iia breast cancer, stage iib breast cancer, stage iii breast cancer, stage iiia breast cancer, stage iiib breast cancer, stage iiic breast cancer, triple-negative breast carcinoma
• Phase: III
• Trial ID: NCT02445391
• Protocol ID: 18-723

Trial Description: The primary objective of this study is to compare the progression-free survival (PFS) between sacituzumab govitecan-hziy (SG) versus treatment of physician's choice (TPC) in participants with previously untreated, locally advanced, inoperable or metastatic triple-negative breast cancer whose tumors do not express programmed cell death ligand 1 (PD-L1) or in participants previously treated with anti-programmed cell death (ligand or protein) 1 (Anti-PD-(L)1) Agents in the early setting whose tumors do express PD-L1.

• Conditions: pd-l1 negative, triple negative breast cancer
• Phase: III
• Trial ID: NCT05382299
• Protocol ID: 22-478

Trial Description: This phase II trial studies how well the combination of avelumab with liposomal doxorubicin with or without binimetinib, or the combination of avelumab with sacituzumab govitecan works in treating patients with triple negative breast cancer that is stage IV or is not able to be removed by surgery (unresectable) and has come back (recurrent). Immunotherapy with checkpoint inhibitors like avelumab require activation of the patient's immune system. This trial includes a two week induction or lead-in of medications that can stimulate the immune system. It is our hope

• Conditions: invasive breast carcinoma, recurrent breast carcinoma, stage iii breast cancer, stage iiia breast cancer, stage iiib breast cancer, stage iiic breast cancer, stage iv breast cancer, triple-negative breast carcinoma, unresectable breast carcinoma
• Phase: II
• Trial ID: NCT03971409
• Protocol ID: 22-468

Trial Description: This is a modular, Phase I/II, multicentre study to investigate CT7001 monotherapy in advanced solid malignancies and to further investigate CT7001 as monotherapy or in combination with standard therapy in specific participant groups with Triple Negative Breast Cancer (TNBC), Castrate Resistant Prostate Cancer (CRPC) and in combination with fulvestrant for patients with hormone receptor-positive (HR+ve) / human epidermal growth factor-2 negative (HER2-ve) breast cancer.

• Conditions: advanced solid malignancies
• Phase: I/II
• Trial ID: NCT03363893
• Protocol ID: 19-827

Trial Description: The purpose of this study was to combine the PDR001 checkpoint inhibitor with each of four agents with immunomodulatory activity to identify the doses and schedule for combination therapy and to preliminarily assess the safety, tolerability, pharmacological and clinical activity of these combinations

• Conditions: colorectal cancer triple negative breast cancer nsclc - adenocarcinoma
• Phase: I
• Trial ID: NCT02900664
• Protocol ID: 16-479

Trial Description: This phase I trial studies the side effects and best dose of olaparib and onalespib when given together in treating patients with solid tumors that have spread to other places in the body (metastatic) or cannot be removed by surgery (unresectable) or ovarian, fallopian tube, primary peritoneal, or triple-negative breast cancer that has come back (recurrent). Olaparib and onalespib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

• Conditions: metastatic high grade fallopian tube serous adenocarcinoma, metastatic malignant solid neoplasm, metastatic primary peritoneal serous adenocarcinoma, metastatic triple-negative breast carcinoma, platinum-resistant fallopian tube carcinoma, platinum-resistant ovarian carcinoma, platinum-resistant primary peritoneal carcinoma, recurrent breast carcinoma, recurrent high grade fallopian tube serous adenocarcinoma, recurrent high grade ovarian serous adenocarcinoma, recurrent primary peritoneal high grade serous adenocarcinoma, recurrent triple-negative breast carcinoma, refractory fallopian tube serous adenocarcinoma, refractory ovarian serous adenocarcinoma, refractory primary peritoneal serous adenocarcinoma, refractory triple-negative breast carcinoma, unresectable high grade fallopian tube serous adenocarcinoma, unresectable malignant solid neoplasm, unresectable primary peritoneal serous adenocarcinoma
• Phase: I
• Trial ID: NCT02898207
• Protocol ID: 17-715

Trial Description: This clinical trial is evaluating a drug called BT5528 alone and in combination with nivolumab in participants with advanced solid tumors historically known for expression of EphA2. The main goals of this study are to: - Find the recommended dose(s) of BT5528 that can be given safely to participants alone and in combination with nivolumab - Learn more about the side effects of BT5528 - Learn about how effective BT5528 is for the treatment of ovarian cancer, urothelial/bladder cancer, lung cancer (NSCLC), triple-negative breast cancer, head and neck cancer (HNSCC), and gastric/upper gastrointestinal cancer. - Learn more about BT5528 therapy alone and in combination with nivolumab.

• Conditions: advanced solid tumor historically known for high epha2 expression, gastric/upper gastrointestinal cancer, head and neck cancer, non-small cell lung cancer, ovarian cancer, triple negative breast cancer, urothelial cancer
• Phase: I/II
• Trial ID: NCT04180371
• Protocol ID: 19-885

Trial Description: The purpose of this study of MCS110 with PDR001 was to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and antitumor activity of the combination of MCS110 with PDR001 in adult patients with solid tumors

• Conditions: endometrial carcinoma, melanoma, pancreatic carcinoma, triple negative breast cancer
• Phase: I/II
• Trial ID: NCT02807844
• Protocol ID: 16-491

Trial Description: This is an open label, Phase 1b/2 study with multiple treatment arms evaluating the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of rucaparib in combination with a second anticancer therapy in participants with an advanced/metastatic solid malignancy (Phase 1b), followed by evaluation of the combination in one or more specific participant populations in an expansion phase (Phase 2 cohorts

• Conditions: ovarian cancer, solid tumor, triple-negative breast cancer, urothelial carcinoma
• Phase: I/II
• Trial ID: NCT03992131
• Protocol ID: 19-168

Trial Description: This research study is studying a drug called Abemaciclib as a possible treatment for have metastatic triple-negative type of breast cancer.

• Conditions: breast cancer
• Phase: II
• Trial ID: NCT03130439
• Protocol ID: 17-024

Trial Description: This research study is studying Ruxolitinib as possible treatment for Inflammatory Breast Cancer (IBC). The Following drugs will be use in combination with Ruxolinitinib. - Paclitaxel (also called Taxol) - Doxorubicin also called Adriamycin - Cyclophosphamide, also called Cytoxan

• Conditions: inflammatory breast cancer (ibc)
• Phase: II
• Trial ID: NCT02876302
• Protocol ID: 16-151

Trial Description: The objective of this study is to assess safety and efficacy of CAB-ROR2-ADC in solid tumors

• Conditions: head and neck cancer, melanoma, non small cell lung cancer, triple negative breast cancer
• Phase: I/II
• Trial ID: NCT03504488
• Protocol ID: 21-248

Trial Description: A Phase 2, clinical study in advanced, metastatic breast cancer that will evaluate CX-2009 monotherapy in both Hormone Receptor(HR) positive/HER2 negative breast cancer and in TNBC, and evaluate CX-2009+CX-072 in TNBC

• Conditions: breast cancer, breast neoplasms, breast neoplasms hormone receptor positive/her2 negative, breast neoplasms triple-negative, neoplasms
• Phase: II
• Trial ID: NCT04596150
• Protocol ID: 21-130

Trial Description: This study is one single group of participants with non-small cell lung cancer (NSCLC) who have not been cured by other treatments. It is the first time the drug has been used in humans. There will be two parts and a sub-study. The primary purpose of the parts are: - Dose Escalation: To investigate the safety and tolerability and to determine the maximum tolerated dose (MTD) and the recommended dose for expansion (RDE) of DS-1062a - Dose Expansion: To investigate the safety and tolerability of DS-1062a in additional solid tumors This study is expected to last approximately

• Conditions: hormone receptor positive breast cancer, non-small cell lung cancer, triple negative breast cancer
• Phase: I
• Trial ID: NCT03401385
• Protocol ID: 18-061

Trial Description: The purpose of this study was to combine the PDR001 checkpoint inhibitor with several agents with immunomodulatory activity to identify the doses and schedule for combination therapy and to preliminarily assess the safety, tolerability, pharmacological and clinical activity of these combinations

• Conditions: colorectal cancer non-small cell lung carcinoma (adenocarcinoma) triple negative breast cancer renal cell carcinoma
• Phase: I
• Trial ID: NCT02890069
• Protocol ID: 16-423

Trial Description: The purpose of this clinical trial is to learn about the safety and effects of study medicine (PF-06873600) when taken alone or with hormone therapy by people with cancer. People may be able to participate in this study if they have the following types of cancer: Hormone Receptor positive (HR+) breast cancer; Human Epidermal Growth Factor Receptor 2 (HER2)-negative breast cancer that is advanced or metastatic (spread to other parts of the body); triple negative breast cancer; epithelial ovarian cancer; fallopian tube cancer; or primary peritoneal cancer. All participants

• Conditions: hr+ her2- metastatic breast cancer ovarian cancer fallopian tube cancer primary peritoneal cancer triple negative breast cancer male breast cancer
• Phase: I/II
• Trial ID: NCT03519178
• Protocol ID: 19-676

Trial Description: This is a phase I/Ib, open label study. The escalation portion will characterize the safety and tolerability of DKY709 and DKY709 in combination with PDR001 in subjects with NSCLC or melanoma who have received prior anti-PD-1/PD-L1 therapy, or subjects with NPC. After the determination of the MTD/RD for a particular treatment arm, dose expansion will further assess safety, tolerability, PK/PD, and anti-tumor activity of each regimen at the MTD/RD

• Conditions: carcinoma non-small-cell lung, melanoma, microsatellite stable colorectal cancer, nasopharyngeal carcinoma, triple negative breast cancer
• Phase: I
• Trial ID: NCT03891953
• Protocol ID: 19-244

Trial Description: A Study of XMT-1660 in Solid Tumors

• Conditions: breast cancer, endometrial cancer, fallopian tube cancer, ovarian cancer, primary peritoneal cavity cancer, triple negative breast cancer
• Phase: I
• Trial ID: NCT05377996
• Protocol ID: 22-547

Trial Description: This research trial is studying a combination of neoadjuvant radiotherapy (RT), immunotherapy (pembrolizumab) and chemotherapy for lymph node-positive, triple negative (TN) or hormone receptor positive/HER2-negative breast cancer. The names of the study interventions involved in this study are: - Radiation Therapy (RT) - Immunotherapy: Pembrolizumab (MK-3475) - Chemotherapies: - Paclitaxel - Doxorubicin (also called Adriamycin) - Cyclophosphamide - Carboplatin (optional, and in TN only) - Capecitabine (optional, and in TN only)

• Conditions: biopsy-proven positive lymph node(s), hormone receptor positive (hr+) her2-negative breast cancer, triple negative breast cancer
• Phase: Feasibility / Pilot
• Trial ID: NCT04443348
• Protocol ID: 20-157

Trial Description: TC-510 is a novel cell therapy that consists of autologous genetically engineered T cells expressing two synthetic constructs: first, a single-domain antibody that recognizes human Mesothelin, fused to the CD3-epsilon subunit which, upon expression, is incorporated into the endogenous T cell receptor (TCR) complex and second, a PD-1:CD28 switch receptor, which is expressed on the surface of the T cell, independently from the TCR. The PD-1:CD28 switch receptor comprises the PD-1 extracellular domain fused to the CD28 intracellular domain via a transmembrane domain. Thus, the switch is designed to produce a costimulatory signal upon engagement with PD-L1 on cancer cells.

• Conditions: cholangiocarcinoma, colorectal cancer, colorectal neoplasms, mesothelioma, mesothelioma peritoneum, mesothelioma malignant, mesotheliomas pleural, non small cell lung cancer, ovarian adenocarcinoma, ovarian cancer, ovarian neoplasms, ovarian serous adenocarcinoma, pancreatic adenocarcinoma, pancreatic cancer, pancreatic neoplasms, tnbc - triple-negative breast cancer, triple negative breast cancer
• Phase: I/II
• Trial ID: NCT05451849
• Protocol ID: 23-026

Trial Description: This is a Phase 1, open-label, dose-escalation and expansion study evaluating the safety, tolerability, PK, antitumor activity, and effect on biomarkers of XL102 administered orally alone and in multiple combination regimens to subjects with advanced solid tumors

• Conditions: epithelial ovarian cancer, hormone receptor positive breast carcinoma, metastatic castration-resistant prostate cancer, neoplasm malignant, triple negative breast cancer
• Phase: I
• Trial ID: NCT04726332
• Protocol ID: 21-057

Trial Description: The goal of this study is to learn if giving cemiplimab and vidutolimod together could be effective in treating advanced cancer. The main questions it aims to answer are: - How many participants' cancers respond to vidutolimod together with cemiplimab? - Is vidutolimod together with cemiplimab safe and well-tolerated? - How well does vidutolimod together with cemiplimab treat participants' cancer? Participants will receive trial treatment for up to 2 years. 30 days after stopping treatment, participants will have an end of treatment visit. After that visit, the trial staff will continue to follow up with participants about every 3 months, until the trial ends.

• Conditions: basal cell carcinoma, cutaneous squamous cell carcinoma, merkel cell carcinoma, non-small cell lung cancer, triple negative breast cancer
• Phase: II
• Trial ID: NCT04916002
• Protocol ID: 21-606

Trial Description: In this four-part study, NKTR-214 was administered in combination with nivolumab and with/without other anticancer therapies. Part 1 considered escalating doublet (NKTR 214 + nivolumab) doses to determine the RP2D. Part 2 considered dose expansion cohorts for the doublet (NKTR 214 + nivolumab ± chemotherapy). Part 3 was schedule-finding for a triplet therapy (NKTR 214 + nivolumab + ipilimumab). Part 4 dose expansion for the triplet (NKTR 214 + nivolumab + ipilimumab) was planned to further assess the efficacy of the RP2D triplet combination at dosing schedules from Part 3

• Conditions: gastric cancer, hr+/her2- breast cancer, melanoma, non small cell lung cancer, renal cell carcinoma, triple negative breast cancer, urothelial carcinoma
• Phase: I/II
• Trial ID: NCT02983045
• Protocol ID: 17-310

Trial Description: This research study is studying the usefulness of magnetic resonance imaging (MRI) to screen for brain metastases (spread of the breast cancer to the brain).

• Conditions: breast cancer, her2-positive breast cancer, hormone receptor positive malignant neoplasm of breast, inflammatory breast cancer, metastatic breast cancer, triple negative breast cancer
• Phase: II
• Trial ID: NCT04030507
• Protocol ID: 19-066

Trial Description: This is a Phase 1a/1b, open-label, multicenter, global, dose-escalation study designed to evaluate the safety, tolerability, immune response, and pharmacokinetics of autogene cevumeran (RO7198457) as a single agent and in combination with atezolizumab (MPDL3280A, an engineered anti-programmed death-ligand 1 [anti-PD-L1] antibody

• Conditions: bladder cancer, colorectal cancer, head and neck cancer, melanoma, non-small cell lung cancer, other solid cancers, renal cancer, triple negative breast cancer
• Phase: I
• Trial ID: NCT03289962
• Protocol ID: 18-051

Trial Description: This is a multicenter Phase 1b, open-label study to assess safety, tolerability, preliminary efficacy, and pharmacokinetics (PK) of cabozantinib taken in combination with atezolizumab in subjects with multiple tumor types, including advanced urothelial carcinoma (UC) (including bladder, renal pelvis, ureter, urethra), renal cell carcinoma (RCC), castration-resistant prostate cancer (CRPC), non-small-cell lung cancer (NSCLC), triple negative breast cancer (TNBC), ovarian cancer (OC), endometrial cancer (EC), hepatocellular cancer (HCC), gastric cancer/gastroesophageal

• Conditions: castration-resistant prostate cancer, colorectal cancer, differentiated thyroid cancer, endometrial cancer, gastric cancer, gastroesophageal junction adenocarcinoma, head and neck cancer, hepatocellular carcinoma, lower esophageal cancer, non-small cell lung cancer, ovarian cancer, renal cell carcinoma, triple negative breast cancer, urothelial carcinoma
• Phase: I
• Trial ID: NCT03170960
• Protocol ID: 17-492

Trial Description: The clinical study will assess the safety and tolerability of escalating intratumoral doses of mRNA-2752 in participants with relapsed/refractory solid tumor malignancies or lymphoma

• Conditions: dose escalation: relapsed/refractory solid tumor malignancies or lymphoma, dose expansion: triple negative breast cancer hnscc non-hodgkins urothelial cancer immune checkpoint refractory melanoma and nsclc lymphoma
• Phase: I
• Trial ID: NCT03739931
• Protocol ID: 18-518

Trial Description: The main purpose of this 3-part study is to evaluate the safety and efficacy of the study drug known as LY2880070 in participants with advanced or metastatic solid tumors

• Conditions: breast cancer, colon cancer, colorectal cancer, endometrial cancer, neoplasms, ovarian cancer, pancreas cancer, pancreatic cancer, rectal cancer, soft tissue sarcoma, solid tumors, triple negative breast cancer
• Phase: I
• Trial ID: NCT02632448
• Protocol ID: 18-524

Trial Description: ONCR-177-101 is a phase 1, open-label, multi-center, dose escalation and expansion study of ONCR-177, an oncolytic Herpes Simplex Virus for intratumoral injection, alone and in combination with PD-1 blockade in adult subjects with advanced and/or refractory cutaneous, subcutaneous or metastatic nodal solid tumors or with Liver Metastases of Solid Tumors. The purpose of this study is to determine the maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D), as well as to evaluate preliminary efficacy

• Conditions: advanced solid tumor, breast cancer, cancer, colorectal carcinoma, liver metastases, melanoma, non-melanoma skin cancer, solid tumor, squamous cell carcinoma of head and neck, triple negative breast cancer
• Phase: I
• Trial ID: NCT04348916
• Protocol ID: 20-135

Trial Description: This is an open-label, multicenter, first in human, Phase 1a/1b study of PY314 in subjects with locally advanced (unresectable) and/or metastatic solid tumors that are refractory or relapsed to standard of care (including pembrolizumab, if approved for that indication

• Conditions: advanced solid tumor, breast cancer, colorectal cancer, gynecologic cancer, hormone receptor/growth factor receptor-negative breast cancer, lung adenocarcinoma, ovarian cancer, renal cell carcinoma, triple negative breast cancer
• Phase: I/II
• Trial ID: NCT04691375
• Protocol ID: 21-599

Trial Description: This study will test the safety, including side effects, and determine the characteristics of a drug called PRO1184 in participants with solid tumors. Participants will have solid tumor cancer that has spread through the body (metastatic) or cannot be removed with surgery (unresectable). This study will have two parts. Part A of the study will find out how much and how frequently PRO1184 should be given to participants. Part B will use the dose and schedule found in Part A to find out how safe PRO1184 is and if it works to treat solid tumor cancers.

• Conditions: endometrial cancer, fallopian tube cancer, her2-negative breast cancer, hormone receptor-positive breast cancer, mesothelioma, non-small cell lung cancer, ovarian cancer, primary peritoneal carcinoma, triple negative breast cancer
• Phase: I/II
• Trial ID: NCT05579366
• Protocol ID: 23-007

Trial Description: The primary purpose of this study is to find the recommended dose of LGK974 as a single agent and in combination with PDR001 that can be safely given to adult patients with selected solid malignancies that have progressed despite standard therapy or for which no effective standard therapy exists

• Conditions: braf mutant colorectal cancer, cervical squamous cell cancer, esophageal squamous cell cancer, head and neck squamous cell cancer, lung squamous cell cancer, melanoma, pancreatic cancer, triple negative breast cancer
• Phase: I
• Trial ID: NCT01351103
• Protocol ID: 15-129

castration-resistant prostate cancer) will be randomized to receive either NUV-868 monotherapy, enzalutamide monotherapy, or the combination of NUV-868 + enzalutamide. Patients will self-administer NUV-868 orally daily in 28-day cycles as monotherapy in Phases 1 and 2. In Phases 1b and 2, patients will self-administer NUV-868 orally daily in 28-day cycles in combination with olaparib or enzalutamide daily at standard prescribed doses (Phase 1b) or at the recommended Phase 2 combination dose (RP2cD) that is determined in Phase 1b. Patients will be treated until disease progression, toxicity, withdrawal of consent, or termination of the study.

• Conditions: advanced solid tumor, breast cancer, breast carcinoma, breast tumor, cancer of breast, cancer of ovary, cancer of pancreas, cancer of prostate, cancer of the breast, cancer of the ovary, cancer of the pancreas, cancer of the prostate, castrate resistant prostate cancer, castration resistant prostatic cancer, castration resistant prostatic neoplasms, ovarian cancer, ovary cancer, ovary neoplasm, pancreas cancer, pancreas neoplasm, pancreatic cancer, prostate cancer, prostate neoplasm, prostatic cancer, triple negative breast cancer, triple negative breast neoplasms, triple-negative breast cancer
• Phase: I/II
• Trial ID: NCT05252390
• Protocol ID: 23-063